Severe	severe	O	O	O	O
immune	immune	O	O	O	O
hemolytic	hemolytic	O	DISEASE	OTHERS	I
anemia	anemia	O	DISEASE	OTHERS	I
associated	associated	O	O	O	O
with	with	O	O	O	O
prophylactic	prophylactic	O	O	O	O
use	use	O	O	O	O
of	of	O	O	O	O
cefotetan	cefotetan	O	O	OTHERS	I
in	in	O	O	O	O
obstetric	obstetric	O	O	O	O
and	and	O	O	O	O
gynecologic	gynecologic	O	O	O	O
procedures	procedures	O	O	O	O
.	.	O	O	O	O

Second-	second-	O	O	O	O
and	and	O	O	O	O
third-generation	third-generation	O	O	O	O
cephalosporins	cephalosporins	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
especially	especially	O	O	O	O
cefotetan	cefotetan	O	O	OTHERS	I
,	,	O	O	O	O
are	are	O	O	O	O
increasingly	increasingly	O	O	O	O
associated	associated	O	O	O	O
with	with	O	O	O	O
severe	severe	O	O	O	O
,	,	O	O	O	O
sometimes	sometimes	O	O	O	O
fatal	fatal	O	O	O	O
immune	immune	O	O	O	O
hemolytic	hemolytic	O	DISEASE	OTHERS	I
anemia	anemia	O	DISEASE	OTHERS	I
.	.	O	O	O	O

We	we	O	O	O	O
noticed	noticed	O	O	O	O
that	that	O	O	O	O
10	10	O	O	O	O
of	of	O	O	O	O
our	our	O	O	O	O
35	35	O	O	O	O
cases	cases	O	O	O	O
of	of	O	O	O	O
cefotetan-induced	cefotetan-induced	O	O	O	O
hemolytic	hemolytic	O	O	OTHERS	I
anemias	anemias	O	O	OTHERS	I
were	were	O	O	O	O
in	in	O	O	O	O
patients	patients	O	O	O	O
who	who	O	O	O	O
had	had	O	O	O	O
received	received	O	O	O	O
cefotetan	cefotetan	O	O	OTHERS	I
prophylactically	prophylactically	O	O	O	O
for	for	O	O	O	O
obstetric	obstetric	O	O	O	O
and	and	O	O	O	O
gynecologic	gynecologic	O	O	O	O
procedures	procedures	O	O	O	O
.	.	O	O	O	O

Eight	eight	O	O	O	O
of	of	O	O	O	O
these	these	O	O	O	O
cases	cases	O	O	O	O
of	of	O	O	O	O
severe	severe	O	O	O	O
immune	immune	O	O	O	O
hemolytic	hemolytic	O	DISEASE	OTHERS	I
anemia	anemia	O	DISEASE	OTHERS	I
are	are	O	O	O	O
described	described	O	O	O	O
.	.	O	O	O	O

